Following completion of Phase 1 clinical development, AbbVie has an option to license the vectorized tau antibody program and would then lead further clinical development and global commercialization for tauopathies
, including Alzheimer's disease and other neurodegenerative diseases.
The company currently has operations in Taiwan, China, and Japan and its pipeline features three diagnostic and two therapeutic product candidates, focusing on Alzheimer's Disease, non-AD tauopathies
, Lewy Body dementia, and Parkinson's Disease.
However, since the prion hypothesis has not yet been definitively shown in human tauopathies
, the concept in association with AD and related tauopathies
The following findings do not exclude the application of CARTS terminology for reasons that are further clarified below: the absence of morphologic HS (although frequently present), the absence of severe cerebral arteriolosclerosis (although frequently present), and/or the presence of other degenerative brain diseases, including [alpha]-synucleinopathies, and non-AD tauopathies
, such as PART, progressive supranuclear palsy, and argyrophilic grain disease.
Moreover, Biogen recently paid Bristol Myers-Squibb $300 million upfront, plus as much as $410 million for milestones and potential royalties, for BMS-986168, a Phase II-ready antibody targeting extracellular tau, the protein that forms the deposits in the brain associated with Alzheimer's Disease and other neurodegenerative tauopathies
such as Progressive Supranuclear Palsy.
Rahman, Tau Pathology in Alzheimer Disease and other Tauopathies
are neurodegenerative conditions characterized by a pathologic accumulation of insoluble intraneuronal aggregates of tau proteins (Figure 1) leading to various frontotemporal dementias.
PET Imaging of Tau Pathology in Alzheimer's Disease and Tauopathies
Protein aggregates/inclusions have been recognized in several neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, tauopathies
, and synucleinopathies (l2).
Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies
It also reviews key players involved in the therapeutic development for Tauopathies
and special features on late-stage and discontinued projects.
Furthermore, as one kind of sleep disorders, RBD has been reported in 38-75% of neurological disorders particularly in neurodegenerative disorders characterized by intraneuronal deposition of [alpha]-synuclein (synucleinopathies, such as PD, MSA, and DLB), but it is rare in tauopathies
such as PSP .